Latest Share Chat

REMOVE ADS

Avacta Group Share News (AVCT)

Avacta Group Information

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

71.00 -5.00 (-6.67%)

Bid:

70.00

Ask:

72.00

Spread: 2.00 (2.857%)

Market Cap: £318.58m

Last checked at -

Intraday Avacta Group Share Chart

REMOVE ADS

Avacta Group News

EARNINGS AND TRADING: Kenmare meets guidance, plans to lower costs

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

Avacta to start trialling second drug after FDA clearance

(Sharecast News) - Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the investigation...

EARNINGS AND TRADING: Treatt cuts dividend after "challenging year"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reporte...

Avacta reports strong operational progress

(Sharecast News) - Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company advanced i...

Avacta upbeat on fresh data from second oncology asset

(Sharecast News) - Avacta reported new pharmacology data on its second oncology asset, FAP-Exd (AVA6103), on Thursday, showing sustained tumor exposur...

Avacta reports 'clinically meaningful' tumour shrinkage in AVA6000 trial

(Sharecast News) - Avacta Therapeutics said on Wednesday that new data from the phase 1b cohort of its ongoing trial of faridoxorubicin, also known as...

Avacta says salivary gland cancer drug shrinks tumour

(Alliance News) - Avacta Group PLC on Wednesday said new data demonstrated that its drug caused "robust and meaningful" tumour shrinkage in patients w...

IN BRIEF: Avacta to announce initial phase 1b data on faridoxorubicin

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company - Expects to announce initial faridoxorubicin phase 1b data in the salivary gl...